ASH 2018: Ninlaro as a Maintenance Therapy After Transplant

This is the first randomized trial which effectively shows a 39% improvement in progression free survival of an proteasome inhibitor over no maintenance.  This now becomes another possible available maintenance strategy.  When compared to a previous trial of lenalidomide vs. placebo after stem cell transplant the improvement with lenalidomide was over 100%, however the survival rate after a median follow up of 86 months was only 18%.  The Ixazomib trial has not a median follow up of just about two years and no data on the difference in Overall Survival was reported.  This should happen in the future, and will be the true measure of Ixazomib as a single agent for maintenance.